替格瑞洛药物不良反应的分析
|
摘要
目的分析替格瑞洛药物不良反应(ADRs)的发生和分布的一般规律,为临床合理用药提供依据。方法检索截至2018-10-31中国医院知识总库、维普、万方及Pub Med、EMbase等数据库中关于替格瑞洛ADRs的文献。用Endnote软件及人工方法进行整理,分析文献发表的分布情况,并对ADRs发生类型和程度等信息进行分析汇总。结果共纳入文献32篇。首次发表关于替格瑞洛ADRs的文献是在2012年。涉及替格瑞洛引起ADRs主要为呼吸系统、消化系统、皮肤和皮下组织等。结论替格瑞洛在用药的过程中要加强监测,做好跟踪随访和记录,发现ADRs及时处理,避免病情加重。
Objective To explore the regularity and clinical characteristics of adverse drug reactions( ADRs) induced by ticagrelor in order to provide references for safe and rational medication. Methods Based on the domestic literature retrieved from CHKD,VIP,Wanfang database,and PubMed,EMbase from the establishment of the database to 31 October 2018,Endnote was used to sort and summarize the articles. Distribution of publications and ADRs caused by ticagrelor were summarized and statistically analyzed. Results A total of 32 articles were enrolled. The first publication of ADRs caused by ticagrelor was in 2012. The ADRs induced by ticagrelor were the respiratory system,digestive system,skin and subcutaneous tissue. Conclusion Ticagrelor should be monitored,followed up and recorded,and ADRs should be handled in time to avoid aggravation of the disease.
Objective To explore the regularity and clinical characteristics of adverse drug reactions( ADRs) induced by ticagrelor in order to provide references for safe and rational medication. Methods Based on the domestic literature retrieved from CHKD,VIP,Wanfang database,and PubMed,EMbase from the establishment of the database to 31 October 2018,Endnote was used to sort and summarize the articles. Distribution of publications and ADRs caused by ticagrelor were summarized and statistically analyzed. Results A total of 32 articles were enrolled. The first publication of ADRs caused by ticagrelor was in 2012. The ADRs induced by ticagrelor were the respiratory system,digestive system,skin and subcutaneous tissue. Conclusion Ticagrelor should be monitored,followed up and recorded,and ADRs should be handled in time to avoid aggravation of the disease.
引文
[1]TENG R,OLIVER S,HAYES M,et al.Absorption,distribution,metabolism,and excretion of ticagrelor in healthy subjects[J].Drug Metab Dispos,2010,38(9):1514-1521.
[2]GURBEL P A,BLIDEN K P,BUTLER K,et al.Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies:the RESPOND study[J].Circulation,2010,121(10):1188-1199.
[3]JNEID H,ANDERSON J L,WRIGHT R S,et al.2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction[J].Circulation,2012,60(7):875-910.
[4]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.非ST段抬高急性冠状动脉综合征诊断和治疗指南[J].中华心血管病杂志,2012,40(5):353-367.
[5]ALEXOPOULOS D,XANTHOPOULOU I,GKIZAS V,et al.Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction[J].Circ Cardiovasc Interv,2012,5(6):797-804.
[6]余雄杰,陈锦华,刘生友,等.替格瑞洛致呼吸困难一例[J].中国处方药,2014,12(9):31-32.
[7]李巍,张莹,杜大勇,等.替格瑞洛致呼吸困难38例分析[J].首都食品与医药,2015,22(18):40-42.
[8]边桂芝,钟燕,田雅兰,等.替格瑞洛上市后呼吸系统不良反应信号检测与分析[J].中国新药杂志,2016,25(20):2390-2394.
[9]边桂芝,钟燕,张志勇,等.替格瑞洛上市后出血不良反应信号检测与分析[J].中国医院药学杂志,2016,36(7):557-560.
[10]谢芳.倍林达对氯吡格雷抵抗患者血小板聚集率的影响[J].实用临床医药杂志,2015,19(15):147-148.
[11]陈卫香,唐勇,张亚臣.比伐卢定联合倍林达在经皮冠脉介入治疗患者中的疗效及安全性研究[J].海军医学杂志,2018,39(4):340-344.
[12]TENG R,MITCHELL P,BUTLER K.Effect of age and gender on pharmacokinetics and pharmacodynamics of a single ticagrelor dose in healthy individuals[J].Eur J Clin Pharmacol,2012,68(8):1175-1182.
[13]谢立,张文颖.我院替格瑞洛致不良反应108例分析[J].中国药房,2016,27(29):4085-4087.
[14]王朋.36例替格瑞洛片致出血不良反应报告分析[J].中国药事,2016,30(7):740-744.
[15]KRISAI P,HASCHKE M,BUSER P T,et al.Ticagrelor induced systemic inflammatory response syndrome[J].BMC Cardiovasc Disord,2017,17(1):14-16.
[16]KIDO K,WHEELER M B,SERATNAHAEI A,et al.Rhabdomyolysis precipitated by possible interaction of ticagrelor with highdose atorvast-atin[J].J Am Pharm Assoc,2015,55(3):320-323.
[17]ZHANG C,SHEN L,CUI M,et al.Ticagrelor-induced lifethreatening bleeding via the cyclosporine-mediated drug interaction[J].Medicine(Baltimore),2017,96(37):1-3.
[2]GURBEL P A,BLIDEN K P,BUTLER K,et al.Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies:the RESPOND study[J].Circulation,2010,121(10):1188-1199.
[3]JNEID H,ANDERSON J L,WRIGHT R S,et al.2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction[J].Circulation,2012,60(7):875-910.
[4]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.非ST段抬高急性冠状动脉综合征诊断和治疗指南[J].中华心血管病杂志,2012,40(5):353-367.
[5]ALEXOPOULOS D,XANTHOPOULOU I,GKIZAS V,et al.Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction[J].Circ Cardiovasc Interv,2012,5(6):797-804.
[6]余雄杰,陈锦华,刘生友,等.替格瑞洛致呼吸困难一例[J].中国处方药,2014,12(9):31-32.
[7]李巍,张莹,杜大勇,等.替格瑞洛致呼吸困难38例分析[J].首都食品与医药,2015,22(18):40-42.
[8]边桂芝,钟燕,田雅兰,等.替格瑞洛上市后呼吸系统不良反应信号检测与分析[J].中国新药杂志,2016,25(20):2390-2394.
[9]边桂芝,钟燕,张志勇,等.替格瑞洛上市后出血不良反应信号检测与分析[J].中国医院药学杂志,2016,36(7):557-560.
[10]谢芳.倍林达对氯吡格雷抵抗患者血小板聚集率的影响[J].实用临床医药杂志,2015,19(15):147-148.
[11]陈卫香,唐勇,张亚臣.比伐卢定联合倍林达在经皮冠脉介入治疗患者中的疗效及安全性研究[J].海军医学杂志,2018,39(4):340-344.
[12]TENG R,MITCHELL P,BUTLER K.Effect of age and gender on pharmacokinetics and pharmacodynamics of a single ticagrelor dose in healthy individuals[J].Eur J Clin Pharmacol,2012,68(8):1175-1182.
[13]谢立,张文颖.我院替格瑞洛致不良反应108例分析[J].中国药房,2016,27(29):4085-4087.
[14]王朋.36例替格瑞洛片致出血不良反应报告分析[J].中国药事,2016,30(7):740-744.
[15]KRISAI P,HASCHKE M,BUSER P T,et al.Ticagrelor induced systemic inflammatory response syndrome[J].BMC Cardiovasc Disord,2017,17(1):14-16.
[16]KIDO K,WHEELER M B,SERATNAHAEI A,et al.Rhabdomyolysis precipitated by possible interaction of ticagrelor with highdose atorvast-atin[J].J Am Pharm Assoc,2015,55(3):320-323.
[17]ZHANG C,SHEN L,CUI M,et al.Ticagrelor-induced lifethreatening bleeding via the cyclosporine-mediated drug interaction[J].Medicine(Baltimore),2017,96(37):1-3.